Enoxaparin in acute coronary syndromes

Area of Science:

• Cardiology
• Pharmacology
• Thrombosis

Background:

• Enoxaparin is a low-molecular-weight heparin (LMWH) derivative.
• It functions as an anticoagulant via antithrombin III, inhibiting factor Xa and thrombin IIa.
• Compared to unfractionated heparin (UFH), enoxaparin offers improved bioavailability and predictable anticoagulation, enabling fixed dosing without monitoring.

Purpose of the Study:

• To evaluate the efficacy and safety of enoxaparin in managing acute coronary syndromes.
• To compare enoxaparin with unfractionated heparin (UFH) in cardiovascular event reduction and bleeding risk.

Main Methods:

• Review of clinical trials and meta-analyses assessing enoxaparin in acute coronary syndromes.
• Analysis of efficacy in reducing cardiovascular events and mortality.
• Assessment of safety profiles, including incidence of heparin-induced thrombocytopenia and major bleeding complications.

Main Results:

• Enoxaparin demonstrated consistent efficacy in reducing cardiovascular events and mortality in patients with acute coronary syndromes.
• Initial studies suggested comparable safety to UFH in conservative management.
• Recent data indicate a potential increase in major hemorrhagic complications with enoxaparin in the era of early revascularization, despite clinical benefits.

Conclusions:

• Enoxaparin is a viable alternative to UFH for unstable angina/non-ST-elevation myocardial infarction and ST-elevation myocardial infarction.
• The benefits of enoxaparin in reducing clinical events must be weighed against a modest increase in bleeding risk.
• Clinical decision-making should consider the evolving treatment landscape and patient-specific risk factors.